Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Efficacy of a venetoclax-based, anthracycline-free regimen in newly diagnosed CBFβ::MYH11(+) acute myeloid leukemia

View Full Paper
Ask AI
Bookmark
Share

Authors

ZFZiyu FengJCJia ChenHDHaiping Dai

Discussion

Loading...

Member takes

Overview

Retrospective analysis shows treatment response in acute myeloid leukemia, suggesting Venetoclax offers safe remission alternatives.

Key Points

  • Treatment response improved using venetoclax in acute myeloid leukemia patients, with low toxicity observed.
  • Overall survival rates were similar for venetoclax and traditional therapies after significant follow-up.
  • Retrospective analysis of 81 patients revealed comparable efficacy between venetoclax and anthracycline-based regimens.
  • Lower incidences of severe side effects in the venetoclax group highlight its favorable safety profile.

Cite This Study

Feng et al. (2025) studied this question.

synapsesocial.com/papers/69362f764fa91c937236e3c0https://doi.org/10.1182/blood-2025-1674
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Genotype-guided comparison of ven-HMA versus intensive chemotherapy in newly diagnosed intermediate-risk AML: A multicenter real-world study2025
  2. 2Clinical efficacy and safety of venetoclax combined with hypomethylating agents in relapsed high-risk acute myeloid leukemia patients after allogeneic hematopoietic stem cell transplantation2025 · 4 citations
  3. 3Venetoclax, azacitidine, and chidamide in combination with cytarabine, aclarubicin, and G-CSF as induction chemotherapy for myelodysplasia-related acute myeloid leukemia2026
  4. 4IDH1 mutation predicts response and survival in treatment-naïve Acute Myeloid Leukemia patients receiving with venetoclax with a hypomethylating agent2025
  5. 5Venetoclax plus hypomethylating agents versus priming regimen as the first-line therapy for newly diagnosed acute myeloid leukemia with myelodysplasia-related changes: a propensity score-matched analysis2025